Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 PK, safety, and tolerability of VX-659/tezacaftor/ivacaftor in children with cystic fibrosis (ages 6–11)
2018-001711-67Phase 3
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of bamocaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Cmax of VX-659, tezacaftor, and ivacaftor (Part A).
02
Drugs
bamocaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-001711-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001711-67.